Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03963635
Other study ID # 12251305
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 1, 2019
Est. completion date December 31, 2020

Study information

Verified date August 2019
Source MicroB-plex, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

There are more than 300,000 new cases of Lyme disease every year in the US. Lyme disease is a dangerous bacterial infection transmitted by tick bites and it becomes increasingly severe as the infection progresses. Definitive diagnosis is based on serum-based tests that have fundamental limitations: 1) current tests cannot detect early infections so patients do not receive antibiotic therapy until the infection has progressed, and 2) there is no way to measure if antibiotic therapy has been successful. MicroB-plex will address these two unmet clinical needs by introducing a novel, blood-based diagnostic method that will enable clinicians to diagnose infections earlier and to monitor the success of their interventions.


Description:

Lyme disease is the most commonly reported arthropod-borne infection in the US with recent CDC estimates eclipsing 300,000 new cases in 2013. In addition to growing in frequency, the infections have a complex and increasingly severe course. Beginning with mild flu-like symptoms and frequently a signature bull's-eye rash, erythema migrans, Lyme disease can progress to severe articular, neurological and cardiac symptoms, most of which are preventable with early antibiotic therapy. Leading investigators have identified two major shortcomings to the current serology-based methods for the definitive diagnosis of Early Localized Lyme disease. First, the clinical sensitivity in the first four weeks is poor, under 50% at the time of symptom onset, so many patients remain undiagnosed or unconfirmed until the disease has had time to progress. Second, serum antibody levels remain elevated long after the infection has been resolved making the monitoring of therapeutic success or diagnosis of re-infection virtually impossible. MicroB-plex will address these shortcomings by using a novel sample matrix from circulating antibody secreting cells (ASC) for diagnosis of Lyme disease. This novel matrix is MENSA (medium enriched for newly synthesized antibody). In this study, MicroB-plex and its clinical collaborators will test whether MENSA is effective in early Lyme diagnostic (within the first 2 weeks) and if this new approach will track therapeutic success.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 31, 2020
Est. primary completion date December 31, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 80 Years
Eligibility Inclusion Criteria:

1. Human adults at least 21 years of age and no more than 80 years of age at the time of screening.

2. Have the ability to understand the requirements of the study, provide written informed consent (including consent for the use and disclosure of research-related health information), and comply with the study protocol procedures (including required study visits).

3. High clinical suspicion of acute Lyme disease, with symptoms seven days or less.

4. Must have erythema migrans rash and physician diagnosis of early Lyme disease.

5. Brief history and physical exam will be obtained during the study visit.

6. Be willing to return to our clinic for up to nine visits and blood draws over a one-year period.

7. People who do not have Lyme disease, but want to participate as healthy controls (one time visit)

Exclusion Criteria:

1. Have poor venous access.

2. Have received any immunosuppressive therapy including biologics or recent course of steroids, or recent chemotherapy.

1. Anti-TNF therapy (eg, adalimumab, etanercept, infliximab).

2. Intravenous (IV) cyclophosphamide

3. Interleukin-1 receptor antagonist (anakinra).

4. Intravenous immunoglobulin (IVIG).

5. High dose prednisone or equivalent (> 100 mg/day).

6. Plasmapheresis.

7. Any new immunosuppressive/immunomodulatory agent

8. Any steroid injection (eg, intramuscular, intraarticular, or intravenous).

3. On treatment for Lyme disease greater than seven days

4. Recent chemotherapy

5. History of solid organ transplant

6. History of autoimmune disorders (SLE, Rheumatoid arthritis, Scleroderma, etc.)

7. History of inflammatory muscle disease (polymyositis, dermatomyositis, etc.)

8. History of inflammatory bowel disease (Crohn's disease, Ulcerative colitis, etc.)

9. History of HIV infection

10. Received a Lyme disease vaccine in the past

11. History of prior Lyme disease infection in the past

12. Have any condition that, in the opinion of the principal investigator, would significantly increase the risk for the subject.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
MicroB-plex Lyme Immunoassay
Subject's blood and clinical data are collected to develop a diagnostic immunoassay

Locations

Country Name City State
United States Johns Hopkins University School of Medicine Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
MicroB-plex, Inc. Johns Hopkins University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of EM positive patients who become MicroB-plex Lyme test positive prior to seroconversion MicroB-plex Lyme Test, that measures anti-Lyme antibodies in MENSA, becomes positive prior to conventional Lyme immunoassays that measure antibodies in serum, resulting in earlier diagnosis Within 14 days of enrollment
Primary Percentage of treated EM positive patients who become MicroB-plex Lyme test negative prior to their decline in serum MicroB-plex Lyme Test, that measures anti-Lyme antibodies in MENSA, becomes negative with successful treatment, prior to a decline in serum antibody level in conventional immunoassays, providing an earlier measure of effective therapy Up to one year from enrollment
Secondary Percentage of treated EM positive patients who remain MicroB-plex Lyme test positive following treatment MicroB-plex Lyme Test, that measures anti-Lyme antibodies in MENSA, remains positive with treatment failure Up to one year from enrollment
See also
  Status Clinical Trial Phase
Completed NCT01207739 - Persistent Lyme Empiric Antibiotic Study Europe Phase 4
Terminated NCT04577053 - PEMF Therapy to Treat Lingering Symptoms of Lyme Disease After Treatment With Antibiotics N/A
Completed NCT04867473 - Feasibility of Teleyoga for Treatment of Lyme Disease N/A
Recruiting NCT04038346 - Symptomatic Management of Lyme Arthritis Phase 3
Completed NCT01143558 - Searching for Persistence of Infection in Lyme Disease Early Phase 1
Withdrawn NCT04318925 - Evaluation and Follow-up of People With Tick-borne Diseases
Terminated NCT03581279 - Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel N/A
Enrolling by invitation NCT05041595 - Lyme Disease Diagnostic Assay - Collection of Whole Blood
Recruiting NCT03981874 - Peripheral Facial Paralysis Sequelae in Lyme Disease Among Children N/A
Terminated NCT03084614 - CD8 Reactivity to Microorganisms in Blood and Breast Milk
Recruiting NCT04835792 - Biomarker Study of Previously Treated Lyme Disease Volunteers in Comparison to Healthy Volunteers
Recruiting NCT06397794 - Navigating Pregnancy and Parenthood With Lyme Disease
Recruiting NCT04148222 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Lyme Disease
Terminated NCT03201042 - Lyme Test Indication Combinations (LyTIC) Study
Completed NCT01368341 - Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice Phase 4
Terminated NCT00958139 - Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes Phase 3
Recruiting NCT00001539 - A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations
Recruiting NCT03501407 - Understanding Tick-borne Diseases
Completed NCT04422314 - ImmuneSense Lyme Study
Recruiting NCT05312619 - The Burden of Lyme Disease (BOLD) in a Pandemic - Insights From an Online Cross-sectional and Prospective Cohort Survey